Market
MindMed’s stock soars 51.5% after FDA grants breakthrough designation to LSD therapy for a form of anxiety
![](https://newyorkdigitalmagazine.com/wp-content/uploads/2024/03/im-51888466-780x470.jpeg)
The FDA’s move will speed up development of MindMed’s LSD-based drug as a treatment for generalized anxiety disorder.
Source link